Bio Medica Laboratories IPO is a book build issue of ₹52.43 crores. The issue is a combination of fresh issue of 0.34 crore shares aggregating to ₹47.19 crores and offer for sale of 0.04 crore shares aggregating to ₹5.24 crores.
Bio Medica Laboratories IPO opens for subscription on May 21, 2026 and closes on May 25, 2026. The allotment for the Bio Medica Laboratories IPO is expected to be finalized on May 26, 2026. Bio Medica Laboratories IPO will list on the NSE SME with a tentative listing date fixed as May 29, 2026.
Bio Medica Laboratories IPO is set issue price band at ₹132 to ₹139 per share. The lot size for an application is 1,000 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,78,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹4,17,000.
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.
Product portfolio:
It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications.
The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh.
IPO stands for "Initial Public Offering." It's the process through which a privately-held company becomes publicly traded by offering its shares to the general public and listing them on a stock exchange for trading. This allows the company to raise capital from investors and grants individuals and institutions the opportunity to invest in and own a portion of the company.
The life cycle of an IPO, or Initial Public Offering, begins with a company's decision to go public. It involves hiring underwriters, registering with regulatory authorities, determining the IPO price, marketing to investors, and the subscription period where investors place orders for shares. After allocation and listing, shares become publicly tradable, and the company enters the secondary market. Ongoing reporting and corporate governance are crucial as the company continues to operate as a publicly-traded entity. The IPO aims to raise capital for growth and provides investors with opportunities to trade shares in the company.
An IPO (Initial Public Offering) is when a private company goes public by selling shares to the public. Investors buy these shares, giving them ownership in the company. It's a way for companies to raise capital and expand. The process involves underwriters, regulatory filings, setting the IPO price, and marketing to investors. After the IPO, shares can be traded on a stock exchange. IPOs offer opportunities and risks, so investors should research and consider carefully.
"Upcoming IPOs" refers to initial public offerings that have been announced by private companies but have not yet occurred. These are companies that plan to go public in the near future by issuing shares to the public and listing them on a stock exchange. Investors often keep an eye on upcoming IPOs as they represent opportunities to invest in companies at their early stages of public trading, potentially capturing growth potential. These offerings are typically accompanied by significant media and investor attention as they approach their launch dates.